Biocardia outlines Japan CardiAMP Shonin submission next quarter with approval expected about 12 months later (NASDAQ:BCDA)
· seekingalpha.com
BioCardia (BCDA) Q2 2026 earnings call recap: Japan PMDA Shonin submission next quarter, FDA updates on CardiAMP/Helix, cash runway—read now.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...